Kornimate/medical-research-clean huggingface dataset:
scapular muscle endurance, shoulder pain, and functionality

Conditions: Rotator Cuff Syndrome of Shoulder and Allied Disorders

Summary: the purpose of this study is to compare scapular muscle endurance (sme), shoulder pain, and functionality of patients with rotator cuff related shoulder pain (rcrsp) with those in the age-gender matched healthy controls and to evaluate the relationship between sme with shoulder pain, and functional impairments in patients with rcrsp.

patients with rcrsp (n:23), and age-gender matched healthy controls (n:23) were included in the study. sme were measured by a one-kilogram dynamometer while the shoulder and elbows are flexed 90°. self-reported pain intensity (activity, night, after sme and fit-hansa) was assessed visual analog scale (vas). functionality was also assessed using the functional impairment test-hand, neck, shoulder, and arm (fit-hansa).

Eligibility criteria:
inclusion criteria: * positive sign in two or more specific shoulder clinical tests; * the presence of rcrsp in magnetic resonance imaging (mri); * at least 120° flexion, 25° abduction, and 30° external rotation movements of the shoulder; * being right arm dominant; * no surgical history in the shoulder region. exclusion criteria: * patients with shoulder pathology other than rcrsp such as glenohumeral instability (capsular and ligamentous lesions, labral lesions, or bone lesions), bicipital tendon lesions, acromioclavicular joint osteoarthritis, glenohumeral joint osteoarthritis, adhesive capsulitis, shoulder or cervical surgery history, * neurological and systemic inflammatory diseases, * bilateral shoulder complaints, * cardiovascular system diseases, * pregnancy, * underwent shoulder-related physical therapy within the past three months.

Keywords: scapula endurance disability rotator cuff lesions
study of different kinds of ear tubes

Conditions: Recurrent Acute Otitis Media; Otitis Media With Effusion With Hearing Impairment

Summary: there are different kinds of ear tubes that may be inserted into the tympanic membrane to relieve recurrent acute otitis and hearing impairment due to otitis media with effusion. the tubes differ in size, shape and material. no-one knows if there are differences between the different kinds of tubes regarding complications. the investigators' hypothesis is that there is differences between the different kinds of tubes regarding complications. to test the investigators' hypothesis, the investigators are about to conduct a randomized controlled study of four kinds of tubes having two different material and two different shapes.


Eligibility criteria:
inclusion criteria: * children aged 1-10 planned for bilateral ventilation tubes exclusion criteria: * ongoing ear infection * previous insertion of ventilation tube
onyx™ liquid embolic ide clinical study

Conditions: Peripheral Arterial Hemorrhage; Trauma; GI Bleed; Ulcer; Hemorrhage

Summary: the purpose of this study is to evaluate the safety and effectiveness of onyx™ les in the treatment of subjects with active arterial bleeding in the peripheral vasculature outside of the heart and brain.

this is a pivotal, prospective, multi-center, non-randomized, single arm study. this study will enroll patients with active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by investigator. in this study, peripheral vasculature is defined as outside of the brain and heart. up to 135 subjects will be consented to achieve 119 enrolled at up to 25 sites in the us. this study will have two visits post-index procedure including hospital discharge visit and 30-day follow-up visit. reintervention visits will be captured through 30 days post-index procedure.

Eligibility criteria:
inclusion criteria: 1. patient is ≥ 22 years old. 2. active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by the investigator. in this study, peripheral vasculature is defined as outside the brain and heart. 3. patient or legally authorized representative (lar) is able to provide written consent to participate in the study. 4. life expectancy of \>30 days, in the opinion of the investigator at the time of enrollment. 5. target treatment area is free from prior embolization treatment. exclusion criteria: 1. pregnant or breastfeeding. 2. symptoms of active infection. 3. patient is known to be participating in the study of an investigational drug, biologic, or device. 4. contrast allergy or other contraindication to angiography, ct, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure. 5. known allergy to components of onyx™. 6. target vasculature unsuitable for the delivery of onyx™ based upon physician assessment. 7. more than 4 target lesions will require embolization, in the investigator's opinion after imaging-based assessment.

Keywords: peripheral arterial hemorrhage embolization treatment
a study of oral sapacitabine and oral seliciclib in patients with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: a study of sequential administration of oral sapacitabine and oral seliciclib in patients with advanced solid tumors.

the primary objective of this study is to determine the maximum tolerated dose (mtd) or recommended phase ii doses of sapacitabine and seliciclib administered sequentially or concomitantly. the secondary objectives are to evaluate antitumor activity of this sequential or concomitant treatment and to explore the pharmacodynamic effect of this treatment in skin and peripheral blood mononuclear cells.

Eligibility criteria:
inclusion criteria: * incurable advanced solid tumors that are no longer responding to conventional therapy or for which no effective therapy exists; at the rd of part 1, an extension cohort up to 20 patients with metastatic breast cancer who are known to be brca mutation carriers will be enrolled. * age 18 years or older * ecog 0-2 * life expectancy ≥ 3 months * evaluable disease * adequate bone marrow function * adequate renal function * adequate liver function * at least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities * able to swallow capsules * at least 3 weeks from major surgery * agree to practice effective contraception * ability to understand and willingness to sign the informed consent form exclusion criteria: * previously untreated cns metastases or progressive cns metastases * currently receiving radiotherapy, biological therapy, or any other investigational agents * uncontrolled intercurrent illness including * pregnant or lactating women * known to be hiv-positive * a history of active hepatitis b and/or hepatitis c infection
individualized selection of peep in patients affected by expiratory flow limitation

Conditions: Postoperative Complications; Mechanical Ventilation Complication

Summary: the goal of this clinical trial is to compare different mechanical ventilation settings in patients undergoing laparoscopic surgery and affected by expiratory flow limitation. the main question\[s\] it aims to answer are: * if individualizing mechanical ventilation on expiratory flow limitation can reduce pulmonary postoperative complications; * if patients with expiratory flow limitation have a higher incidence of pulmonary postoperative complications as compared to patients with no expiratory flow limitation; participants will be screened for expiratory fow limitation and patients with positive screening will be randomized into two groups. each group will receive a different intraoperative mechanical ventilation: * personalized positive end-expiratory pressure based on efl * standard of care positive end-expiratory pressure researchers will then compare the two groups to see if the incidence of pulmonary postoperative complications in the first 7 days after surgery is different.


Eligibility criteria:
inclusion criteria: * ages between 18 and 90 years old; * patients undergoing laparoscopic, robotic surgery * surgery performed in elective regimen; * length of mechanical ventilation more than 120 minutes; * presence of invasive pressure monitoring for clinical purposes; exclusion criteria: * age \ 90; * severe chronic obstructive pulmonary disease with gold stage 3 or 4; * length of mechanical ventilation less than 120 minutes; * unplanned conversion to laparotomy surgery; * refusal to participate by the patient; * anesthesia maintenance using desflurane.
a study of intra-tumoral administered mtx110 in patients with recurrent glioblastoma

Conditions: Recurrent Glioblastoma

Summary: a study designed to assess the safety of mtx110 in patients suffering with recurrent glioblastoma. mtx110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the beginning of the study.

a two cohort, ascending dose study of intra-tumoral mtx110 in patients with recurrent glioblastoma. with the aim to assess the safety and also the recommended phase 2 dose of mtx110. the patient will undergo a surgical procedure to insert a programmable pump and catheter system to allow administration of mtx110 directly to the tumour using convection enhanced delivery (ced). cohort a patients will receive one of three potential dose levels of mtx110 as a weekly infusion in order to establish recommended phase 2 dose. this will be based on an accelerated dose titration/3+3 design. cohort b patients will follow the 3+3 study design with the starting concentration established in cohort a. they too will receive mtx110 as a weekly infusion and may undergo catheter repositioning and continued treatment following progression.

Eligibility criteria:
inclusion criteria: * recurrent glioblastoma. * patients must be healthy enough to tolerate surgery and general anesthesia. * estimated life expectancy of greater than 3 months. exclusion criteria: * patients scheduled to undergo or are undergoing re-irradiation for the recurrent tumour. * patients with a history of glioblastoma treatment with carmustine or gliadel® wafers. * patients who cannot undergo mri. * patients may not have received chemotherapy or bevacizumab ≤ 4 weeks, or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide (1 week) prior to starting the study drug. * patients may not have received treatment with tumor treating fields ≤ 1 week prior to starting the study drug. * patients may not be less than 12 weeks from completion of radiation therapy for the primary tumor. * patients with neoplastic lesions in the brainstem, cerebellum, or spinal cord; radiological evidence of active; multifocal disease; extensive subependymal disease (tumor touching subependymal space is allowed); tumor crossing the midline or leptomeningeal disease. * posterior fossa location of the tumor, regardless of its morphology. * prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin (treatment with tamoxifen or aromatase inhibitors or other hormonal therapy that may be indicated in prevention of prior cancer disease recurrence, are not considered current active treatment).
comparison of next generation laser techniques of myopia correction: idesign vs. smile

Conditions: Myopia

Summary: the proposed study seeks to compare visual acuity, tomographic outcomes, biomechanical changes and inflammatory profile of normal eyes (matched for age, refraction and corneal thickness) undergoing idesign and smile procedure. the hypothesis is that idesign may deliver equivalent or better clinical outcomes than smile, by removing less tissue and correcting for higher order aberrations.

idesign is a promising new technique to treat myopia with astigmatism using ocular aberrations measured with a high resolution wavefront sensor.\[1,2\] early studies with idesign platform has established its safety and efficacy in correction of myopia with fewer patients reporting night vision problems.\[1,2\] in keratoconus, idesign has also provided excellent outcomes following collagen crosslinking.3 smile is a recent technique that eliminates creation of flap and appears to achieve similar refractive outcomes as conventional lasik but with less dryness, less inflammation and faster wound healing.\[4,5\] smile corrects lower order aberrations only.\[4,5\] thus, a comparative assessment of idesign and smile is necessary since idesign can potentially give better visual outcomes with lower volume of tissue removal. if lower volume of tissue is removed, it is also hypothesized that the corneal would be more stable biomechanically.\[5\] further, smile does not provide any correction of higher order aberrations. with the inclusion of higher order aberrations in the idesign treatment plan, it is hypothesized that both short and long term outcomes will be better with idesign than with smile.

Eligibility criteria:
inclusion criteria: 1. patients should be between 18 to 50 years of age. 2. patient must have stable myopia for a minimum period of one year (a change of 0.25d or less) as documented by prior clinical records or current spectacle correction. 3. patient must have a corrected distance visual acuity (cdva) of 20/25 or better, 4. patient must have a spherical equivalent refraction less than -10d 5. patient must have refractive astigmatism less than 3d. exclusion criteria: 1. patient must not have a central corneal thickness (cct) less than 480 micrometer 2. patient must not have a calculated residual stromal bed thickness of less than 250 micrometer after the surgery 3. patient must not have symptoms or signs of keratoconus, diabetes, collagen vascular disease, pregnancy, breastfeeding and any prior ocular surgery. 4. patient must not have an inter-ocular difference of more than 1.00 diopter (d) of spherical or 0.50 d of cylindrical refractive error. 5. patient must not be on chronic systemic steroids or other medication that can affect wound healing. 6. patient must not be allergic to primary or alternative medications. 7. patient must not be using rigid contact lenses for the last three weeks or soft contact lenses for at least 1 week before the preoperative evaluation.
treatment of choledocolithiasis by laparoscopic exploration

Conditions: Choledocholithiasis

Summary: there are three treatment options for choledocholithiasis: endoscopic retrograde cholangiopancreatography (ercp) followed by laparoscopic cholecystectomy; laparoscopic exploration of the main bile duct with concomitant cholecystectomy; and open cholecystectomy with exploration of the main bile duct. a retrospective, descriptive, observational study was taken of patients with a diagnosis of cholecystocholedocholithiasis that failed ercp and who underwent laparoscopic cholecystectomy with exploration of the bile duct.

this study was revision of clinical files.

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of cholecyto-choledocholithiasis with failed ercp and who were taken to lcde in the general surgery service exclusion criteria: * less than 18 year old
clinical trial on the use of 25-oh -d vitamin in haemodialysis patients

Conditions: Chronic Renal Failure

Summary: multicentric randomized italian clinical trial, open label, not for profit. to evaluate the efficacy of 25-oh-d vitamin in terms of myocardial infarction, stroke, sudden death, death for other causes in chronic haemodialysis patients. two arms of treatment: 25-oh-d vitamin per os versus no treatment.


Eligibility criteria:
inclusion criteria: * age \>= 18 years * hematic pth level twofold-ninefold the upper limit * hematic level of 25-oh-d vitamin \< 30 ng/ml exclusion criteria: * renal transplant or peritoneal dialysis less than 3 years ago * pregnancy * breastfeeding

Keywords: chronic haemodialysis 25-oh-d vitamin
effect of ascites replacement strategy on time to 1st flatus after ldlt

Conditions: Living Donor Liver Transplantation

Summary: the aim of this study is to evaluate difference in the rate of recovery of intestinal motility according to different ascites replacement strategy after living donor liver transplantation.


Eligibility criteria:
inclusion criteria: * adults (19 years or older) * elective living donor liver transplantation exclusion criteria: * previous abdominal surgery * renal failure requiring renal replacement therapy * contraindications for 5% albumin use 1. condition with potential risk caused by increased circulating plasma (heart failure, renal failure combined with oliguria, pulmonary edema) 2. hemolytic anemia * contraindications for hartmann solution 1. progressive lactic acidosis 2. hypervolemia 3. hypernatremia

Keywords: ascites albumin hartmann's solution postoperative ileus
efficacy of acupuncture for hot flashes in women treated with hormonal therapy for breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to determine if acupuncture is effective in relieving hot flashes in women treated with hormonal therapy for breast cancer.

the purpose of this study is to determine if acupuncture is effective in relieving hot flashes in women treated with hormonal therapy for breast cancer. hormonal therapy is one of the most common treatments for breast cancer in women. unfortunately, many women on hormonal therapy suffer from hot flashes (the sudden sensation of heat throughout the face, neck and chest, with or without shivering and sweating). many medicines have been used to treat hot flashes, but no single medication has been found to work reliably. acupuncture has been shown to be effective for many conditions in western medicine specifically for dry mouth in people who have received radiation to their head and neck, as well as for hot flashes in women during menopause (the "change of life"). in this study, we are investigating whether acupuncture is effective for women suffering hot flashes that result from their treatment of breast cancer.

Eligibility criteria:
inclusion criteria: * female * 18 years of age or older * history of breast cancer who have received hormonal therapy * personal history of hot flashes * patients will be accepted if receiving therapy with traditional allopathic medicines if their hot flashes have persisted after two months exclusion criteria: * receiving therapy with traditional allopathic medicines for hot flashes

Keywords: breast cancer
post-sophrology cancer patients' anxiety report

Conditions: Cancer

Summary: cancer is pathology with a high impact on patients and relatives quality of life. most of the time, it is a stressful trial. professionals have often resort to pharmaceutical solutions, but sometimes, it is not sufficient. so, patients resort to alternative and complementary medicines, as sophrology. in lucien neuwirth cancer institute, patients can benefit from sophrology. anxiety levels have never been reported before and after sessions. indeed, the present study wants to report anxiety levels before, after, and one and three weeks after session. levels of satisfaction will also be reported.

cancer is pathology with a high impact on patients and relatives quality of life. most of the time, it is a stressful trial. professionals have often resort to pharmaceutical solutions, but sometimes, it is not sufficient. so, patients resort to alternative and complementary medicines, as sophrology. in lucien neuwirth cancer institute, patients can benefit from sophrology. anxiety levels have never been reported before and after sessions. indeed, the present study wants to report anxiety levels before, after, and one and three weeks after session. levels of satisfaction will also be reported.

Eligibility criteria:
inclusion criteria: - patient performing at least one session of sophrology in the lucien neuwirth cancer institute exclusion criteria: * protected patient (according to the law), * patient with incapacity to complete questionnaires, * patient with incapacity to perform sophrologic movements.

Keywords: cancer sophrology anxiety hospital anxiety and depression scale
clinical study of approved contact lenses

Conditions: Myopia

Summary: evaluation of johnson \& johnson acuvue vita (senofilcon c) soft contact lenses to the bausch + lomb ultra (samfilcon a) soft contact lenses

to compare the performance of currently marketed johnson \& johnson acuvue vita (senofilcon c) soft contact lenses to the currently marketed bausch + lomb ultra (samfilcon a) soft contact lenses among adapted wearers of acuvue oasys soft contact lenses.

Eligibility criteria:
inclusion criteria: 1. subjects must be between the ages of 18 and 40 years old, inclusive, on the date the informed consent form (icf) is signed and have the capacity to provide voluntary informed consent. 2. subjects must be able to read, understand and provide written informed consent on the institutional review board (irb)/ethics committee (ec) approved icf and provide authorization as appropriate for local privacy regulations. 3. subjects must be willing and able to comply with all treatment and follow-up/study procedures. 4. subjects must be correctable through spherocylindrical refraction to 32 letters (0.3 logmar) or better (distance, high contrast) in each eye. 5. subjects must have clear central corneas and be free of any anterior segment disorders. 6. subjects must be myopic and require contact lens sphere power correction from -0.50 diopter (d) to -6.00 d (considering vertex distance adjustments in both eyes). 7. subjects must be habitual wearers of johnson \& johnson acuvue oasys single vision spherical soft contact lenses in each eye. 8. subjects must use a contact lens care regimen on a routine basis. 9. subjects must agree to wear their study lenses on a daily wear basis for the duration exclusion criteria: 1. subjects participating in any drug or device clinical investigation within two weeks prior to entry into this study and/or during the period of study participation 2. subjects who are women of childbearing potential (those who are not surgically sterilized or postmenopausal) are excluded from participation in the investigation if they meet any one of the following conditions: * she is currently pregnant * she plans to become pregnant during the study * she is breastfeeding 3. subjects with any systemic disease currently affecting ocular health or which in the investigator's opinion may have an effect on ocular health during the course of the study. 4. subjects using any systemic or topical medications that will, in the investigator's opinion, affect ocular physiology or lens performance.